Pradusinstobart Biosimilar – Anti-PD1 mAb – Research Grade

Introduction

Pradusinstobart Biosimilar – Anti-PD1 mAb is a monoclonal antibody (mAb) that has been developed as a biosimilar to the therapeutic antibody pembrolizumab. It is designed to target the immune checkpoint protein PD-1 (programmed cell death protein 1) and has shown promising results in preclinical studies as a potential treatment for various cancers.

Structure of Pradusinstobart Biosimilar

Pradusinstobart Biosimilar is a recombinant humanized IgG4 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable regions of the heavy and light chains are responsible for binding to the PD-1 protein, while the constant regions provide stability and effector functions.

Heavy Chain

The heavy chain of Pradusinstobart Biosimilar consists of 453 amino acids and is divided into four regions: the variable region, the hinge region, the CH2 domain, and the CH3 domain. The variable region contains the complementarity-determining regions (CDRs) that are responsible for binding to PD-1. The hinge region provides flexibility to the antibody, allowing it to bind to its target in various orientations. The CH2 and CH3 domains are responsible for antibody effector functions, such as complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC).

Light Chain

The light chain of Pradusinstobart Biosimilar consists of 214 amino acids and is divided into two regions: the variable region and the constant region. The variable region contains the CDRs that bind to PD-1, while the constant region provides stability to the antibody.

Mechanism of Action

Pradusinstobart Biosimilar works by binding to the PD-1 protein on the surface of immune cells, specifically T cells. PD-1 is an immune checkpoint protein that plays a key role in regulating the immune response. When PD-1 is activated by its ligands, it inhibits T cell activity, allowing cancer cells to evade the immune system. By binding to PD-1, Pradusinstobart Biosimilar blocks this inhibitory signal, allowing T cells to recognize and attack cancer cells.

Therapeutic Applications

Pradusinstobart Biosimilar is being developed as a potential treatment for various cancers, including melanoma, non-small cell lung cancer, and bladder cancer. Preclinical studies have shown that Pradusinstobart Biosimilar can enhance T cell activity and inhibit tumor growth in animal models. It is also being investigated as a combination therapy with other cancer treatments, such as chemotherapy and radiation therapy.

Comparison to Pembrolizumab

Pembrolizumab is a therapeutic antibody that is currently approved for the treatment of several types of cancer. Pradusinstobart Biosimilar is a biosimilar to pembrolizumab, which means it is highly similar in terms of structure, function, and clinical efficacy. However, Pradusinstobart Biosimilar may have a lower cost and increased accessibility compared to pembrolizumab, making it a more affordable option for patients.

Conclusion

Pradusinstobart Biosimilar – Anti-PD1 mAb is a promising therapeutic antibody that has shown potential as a treatment for various cancers. Its unique structure allows it to bind to PD-1 and block its inhibitory signal, enhancing the immune response against cancer cells. With further research and clinical trials, Pradusinstobart Biosimilar may become a valuable addition to the arsenal of cancer treatments available to patients.